Who does Avanos Medical serve among hospital procurement teams and acute-care clinicians?
Hospitals and acute-care clinicians matter because they drive purchases in high-acuity settings; Avanos reported $701.2 million revenue in 2025 as it shifts to higher-margin med-tech, showing rising demand for clinician-preferred devices and contract renewals.
Clinician preference and GPO contracts shape demand; buying cycles skew toward durable, high-reimbursement products, boosting stickiness and margin expansion.
Identifying the target market for Avanos Medical is critical to understanding its pivot from a diversified supplier to a high-margin med-tech specialist; because procurement and clinicians overlap, revenue predictability and pricing power hinge on these buyers - see Avanos SWOT Analysis
Who Is Avanos Really Trying to Reach?
Avanos Medical targets institutional healthcare buyers and clinical end-users: acute-care hospitals/IDNs and GPOs, fast-growing Ambulatory Surgery Centers (ASCs), plus home health and long-term care providers focused on chronic enteral and respiratory care.
Main customer group: Acute-care hospitals and IDNs
Hospitals and health systems drive roughly 55 percent of 2025 revenue via procurement through Integrated Delivery Networks and GPO contracts; clinical buyers in ORs and ICUs prioritize efficacy and workflow fit.
Secondary groups: ASCs, home health, long-term care
Ambulatory Surgery Centers are the fastest-growing channel with a projected 7 percent CAGR; home health and long-term care use Avanos enteral feeding and respiratory solutions for chronic care management.
Customer type and market role
Avanos medical device customers are predominantly B2B institutional buyers (hospitals, IDNs, ASCs, GPOs) with clinician end-users (anesthesiologists, gastroenterologists, pulmonologists, interventional pain physicians, ICU nurse leaders).
Most important segment by revenue
Acute-care hospitals and IDNs are most commercially important, accounting for ~55 percent of 2025 sales and concentrated purchasing through contracts and formularies.
Core target: institutional clinicians and procurement channels
Avanos serves institutional purchasers and clinician specialists who value clinical outcomes and device performance over per-unit price, with ASCs and home-care growth shaping near-term strategy.
- Primary: acute-care hospitals, IDNs, and GPO contracts (drive 55 percent of 2025 revenue)
- Secondary: Ambulatory Surgery Centers (projected 7 percent CAGR) and long-term/home health providers
- Market type: primarily B2B institutional with clinician end-user influence
- Commercially critical: hospital/IDN procurement and ICU/OR clinician adoption
Further context on Avanos customers and ownership is available in this overview: Who Owns Avanos Company
Avanos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Do Avanos's Customers Care About?
Avanos customers prioritize measurable clinical outcomes, faster patient recovery, and lowering total cost per episode; decisions hinge on devices that support opioid-sparing pain protocols, reduce readmissions, and speed discharge.
Clinical outcomes and recovery speed
Providers buy Avanos products to cut complications and accelerate recovery-examples include enteral feeding systems that reduce aspiration risk and respiratory devices that lower ventilation days.
Practical buying drivers: cost per episode
Hospitals and health systems compare total cost per episode, favoring Avanos solutions that demonstrably reduce readmissions and shorten length of stay, improving unit economics.
Emotional and professional confidence
Clinicians choose devices that increase patient safety and professional trust-opioid-sparing pain tools and reliable wound-care kits support caregiver confidence and reputational upside.
What customers value most
Customers value demonstrable reductions in complications, readmission rates, and opioid use; measurable outcomes drive procurement decisions across acute and post-acute settings.
Loyalty and repeat demand
Repeat purchases hinge on clinical evidence, supply reliability, and integration into care pathways-institutions renew contracts when products cut readmissions and shorten LOS.
Why customers choose Avanos
Avanos wins where devices reduce opioid reliance, improve nutrition delivery, and support discharge efficiency-key for hospitals, long-term care, and home health buyers.
What Those Customers Care About
Avanos healthcare customers focus on patient safety, faster recovery, and lower total cost per episode; hospitals and health systems demand devices that enable opioid-sparing perioperative care, reduce readmissions, and shorten length of stay. Clinicians and care teams prioritize reliable performance and evidence of improved outcomes; procurement favors measurable ROI and supply continuity.
- Reduce complications and readmission rates
- Lower total cost per episode and shorten LOS
- Professional confidence from opioid-sparing protocols
- Proven clinical evidence and supply reliability drive purchasing
History of Avanos Company Explained
Avanos PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Where Is Demand Strongest for Avanos?
Demand is strongest in North America, which accounted for roughly 70-75 percent of Avanos sales in 2025, driven by hospitals shifting procedures to lower – cost outpatient settings and growing ASC adoption.
North America: Core Market
Avanos customers are concentrated in North America where hospitals and health systems and ambulatory surgery centers (ASCs) purchase the bulk of surgical, wound care, respiratory, and enteral feeding products; this region mattered most in 2025 because of procedure migration to ASCs and established procurement channels.
EMEA and Asia – Pacific: Targeted Expansion
Avanos healthcare customers are pushing growth in EMEA and Asia – Pacific, where management targets double – digit growth to diversify geographic reliance and reduce exposure to North American concentration.
Strongest by Brand and Subsegment
Avanos is strongest in neonatal and specialty nutrition via the NeoMed brand; Specialty Nutrition Systems net sales rose 9.2 percent to $432.9 million in 2025, reflecting clear NICU demand and hospital/clinic adoption.
Fastest Growing Demand Areas
Demand is growing fastest in ASCs for orthopedic and GI procedures, in NICUs for enteral feeding, and in home health for respiratory and long – term care devices as clinicians and care teams shift care settings.
Where Demand Is Strongest
North America remains the dominant market for Avanos medical device customers, while NICU nutrition and ASC surgical supplies are the clearest pockets of strength; EMEA and Asia – Pacific offer the most important growth runway in 2025-2026.
- North America: 70-75 percent of 2025 sales and strong ASC migration
- EMEA & Asia – Pacific: targeted double – digit expansion
- NeoMed & Specialty Nutrition: net sales $432.9 million, up 9.2 percent in 2025
- Fastest growth: NICU, ASCs, and home health/long – term care providers
Avanos SOAR Analysis
- Complete SOAR Analysis
- Effortlessly Communicate Your Business Strategy
- Investor-Ready Format
- 100% Editable and Customizable
- Clear and Structured Layout
How Does Avanos Keep Its Audience Growing?
Avanos Medical grows its audience by selling consumables that create recurring revenue, integrating adjacent products via tuck-in acquisitions, and shifting core lines to direct sales to strengthen clinician relationships and enter new care settings.
Expanding Clinical Reach and Adjacent Segments
Avanos adds Avanos healthcare customers by acquiring niche assets (Diros Technology in 2023) and cross-selling high-margin radiofrequency ablation and NICU products into hospitals and health systems and outpatient clinics.
Customer Retention Drivers
Consumables account for roughly 55 percent of product revenue, locking in Avanos medical device customers via a razor-and-blade model; service contracts and clinician training further reduce churn.
Loyalty, Repeat Demand, and Ecosystem Stickiness
Repeat purchases of enteral feeding sets and wound-care disposables drive steady demand from long-term care providers and home health; direct-sales moves (e.g., MIC-KEY in the UK from July 2025) deepen clinician relationships.
Strongest Growth Lever in 2025-2026
The primary lever is consumables-led recurring revenue plus tuck-in acquisitions; management projects mid-single-digit organic revenue growth for 2026, supported by NICU and interventional pain momentum.
How Avanos Keeps the Audience Growing
Avanos retains and expands Avanos medical device customers by combining a consumables-heavy revenue mix, targeted acquisitions, and more direct sales to clinicians and hospitals and health systems, yielding recurring demand and entry into adjacent care settings. Read more on commercial strategy How Avanos Company Sells.
- The main customer-base growth driver is consumables making up 55 percent of product revenue
- The strongest retention factor is repeat consumable purchases plus clinician training and service contracts
- The most important loyalty mechanism is product ecosystems (enteral feeding, wound care, pain devices) and direct-sales relationships
- The main risk to durability is pricing pressure and procurement shifts at large hospitals and health systems
Avanos VRIO Analysis
- Covers VRIO Analysis in Details
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
Frequently Asked Questions
Avanos primarily serves institutional healthcare buyers and clinical end-users. Its main customers are acute-care hospitals and IDNs, with GPOs involved in procurement. The company also serves Ambulatory Surgery Centers, home health providers, and long-term care settings that use enteral feeding and respiratory solutions for chronic care
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.